—

Takeda Pharmaceutical Co Ltd ADR (TAK) — the peer cohort

As of 2026-10-12 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Takeda Pharmaceutical Co Ltd ADR ranks 11 of 11 in its cohort on the Closelooknet composite (50/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
TAK Takeda Pharmaceutical Co Ltd ADR 50 71 38 80 ok 2.2%
ROVI.MC Laboratorios Farmaceuticos ROVI 61 28 76 50 warn 31.3%
LNTH Lantheus Holdings Inc 60 70 73 54 info 10.5%
KNSA Kiniksa Pharmaceuticals Ltd 56 94 57 19 ok 4.5%
BHC.TO Bausch Health Companies Inc 55 66 70 82 info 22%
GALDY GALDERMA GROUP AG 55 50 57 26 info 13.2%
FAGR.BR Fagron NV 52 42 54 59 info 11.5%
HALO Halozyme Therapeutics Inc 74 94 94 48 ok 4.9%
DXCM DexCom Inc 66 85 80 35 bull 9.2%
ONC BeiGene, Ltd. 63 76 62 30 info 9%
MEDP Medpace Holdings Inc 63 85 74 28 ok 8.5%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-12

Quick answers

Who are Takeda Pharmaceutical Co Ltd ADR's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Laboratorios Farmaceuticos ROVI (ROVI.MC), Lantheus Holdings Inc (LNTH), Kiniksa Pharmaceuticals Ltd (KNSA), Bausch Health Companies Inc (BHC.TO), GALDERMA GROUP AG (GALDY), Fagron NV (FAGR.BR), Halozyme Therapeutics Inc (HALO), DexCom Inc (DXCM) and others.

How does TAK score against its peers?

Takeda Pharmaceutical Co Ltd ADR's composite reads 50/100, ranking 11 of 11 in its cohort as of 2026-10-12; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.